Actively Recruiting
Fingolimod for Type 2 Diabetes Mellitus
Led by General Hospital of Shenyang Military Region · Updated on 2025-08-21
40
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to explore the efficacy and safety of Fingoland in the treatment of type 2 diabetes. A total of 40 patients were randomly divided into two groups. One group was treated with fingolimod, another group was given guideline based treatment. The changes of islet function in patients with glycosylated hemoglobin, insulin and C-peptide were observed .
CONDITIONS
Official Title
Fingolimod for Type 2 Diabetes Mellitus
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years old
- Clinically diagnosed with type 2 diabetes
- Glycosylated hemoglobin (HbA1c) between 6.5% and 9.5%
- No drug treatment or only one oral diabetes medication in the past 6 months
- Fasting blood glucose less than 13.9 mmol/l for those without medication or less than 13.3 mmol/l for those with medication
- Stable dosage and type of antidiabetic drugs for the past 3 months if taken
- Body mass index (BMI) of 45 kg/m2 or less
- Signed informed consent
You will not qualify if you...
- Type 1 diabetes
- Diabetic complications such as ketoacidosis, hypertonic state, or lactic acidosis
- Allergy to the study drug
- Abnormal liver or kidney function (transaminase > 2.5 times upper limit; creatinine > 133 µmol/L)
- Serious other organ diseases
- Recent serious cardiovascular or cerebrovascular events within past 6 months
- History or presence of certain heart conduction disorders unless pacemaker present
- Prolonged baseline QT interval (male > 450 ms, female > 460 ms)
- Treatment with certain antiarrhythmic drugs
- Systemic infections
- Participation in other clinical trials within past 3 months
- Any other condition deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Neurology, General Hospital of Northern Theater Command
Shenyang, China, 110016
Actively Recruiting
Research Team
H
HuiSheng Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here